Lilly could pay $800M-plus in pact with drug-tech firm
The companies will work on coupling therapies from Lilly with technology from Halozyme Therapeutics that helps the body disperse and spread medicine.
Pharmaceutical
Articles
FDA OKs once-a-day insulin that could be blockbuster for Lilly
The FDA said Wednesday it approved Basaglar based on data showing it is safe and effective and works similarly to Lantus, the world’s top-selling insulin.
Autism likelier when antidepressants taken during pregnancy
A new study says women who took a common class of antidepressants during the second and third trimesters were more than twice as likely than other women to have children who later developed autism.
Eli Lilly ends development of promising insulin drug
Eli Lilly said Friday that it decided to stop developing the insulin peglispro after learning that it would take more time and cost more than expected to understand a significant side effect.
Experts see big premium increases for Medicare drug plan
With time running out on open-enrollment season, many seniors are facing sharply higher costs for Medicare's popular prescription drug program after a long stretch of stable premiums.
Pfizer-Allergan $160B deal forms world’s largest drugmaker
It's also the largest so-called inversion, where an American corporation combines with a company headquartered in a country with a lower corporate tax rate, saving potentially millions each year in U.S. taxes.
U.S. doctors group calls for drug advertising ban
In a vote Tuesday, the American Medical Association called for an end to television commercials and magazine spreads that are used to pitch prescription drugs directly to consumers.
Bosma backs proposal to require pseudoephedrine prescription
Bosma’s support could give the proposal its first real life in the General Assembly, which has for years eschewed prescription proposals in favor of laws that require pharmacies to track the people who purchase drugs containing pseudoephedrine, one of the ingredients that can be used to make meth.
Despite wealth of attention, new female libido pill isn’t selling
The number of prescriptions for Addyi, the women’s libido-boosting pill, in its first few weeks? 227.
Lilly, other drugmakers face federal pricing probe
Indianapolis-based Eli Lilly and Co. and other U.S. drugmakers are being investigated by federal prosecutors over their drug-pricing practices related to Medicare and Medicaid, according to newspaper reports.
Soaring Rx costs lift firm’s prospects, job creation
Rx Help Centers assists employers and customers as they navigate through the confusing web of prescription drug discounts. Business is so good that the company hopes to add 250 workers by 2017.
Pharmaceutical firms losing business to darknet drug deals
For the $300 billion pharmaceutical industry, the rapid growth of illegal underground marketplaces is a serious threat to profits and reputations.
UPDATE: Lilly halts work on potential blockbuster cholesterol drug
Eli Lilly shares plunged nearly 10 percent Monday morning after it said it would stop development of evacetrapib, an experimental cholesterol drug with blockbuster potential.
Lilly stock climbs on positive arthritis drug test
A potential rheumatoid arthritis treatment from drugmakers Eli Lilly and Co. and Incyte Corp. fared better than another drug in late-stage testing, Lilly said Tuesday.
Settlement clears way for Lilly to launch once-a-day insulin
The settlement with France-based Sanofi SA clears up uncertainty over a drug that could rack up more than $1 billion in sales by 2020, according to Wall Street analysts.
Purdue’s Chao Center regains drug, slashes $360-per-pill price
An Indiana not-for-profit has dropped the price of a drug for multi-drug resistant tuberculosis roughly 90 percent after re-acquiring rights to the medicine from Rodelis Therapeutics.
Lilly stock performs big despite analyst projections
Analysts have consistently given the Indianapolis-based company some of the lowest ratings among a group of 16 large drugmakers, but Lilly shares have been on a five-year rally.
Group urges Dems to tackle pharmaceutical prices
Pharmaceutical industry members are likely to dislike the proposal, which would require them disclose how much they spend on research and development, production, and sales and marketing.
Jardiance study lifts Lilly shares to 15-year high
Eli Lilly shares soared Thursday after study results showed Jardiance sharply reduced chances of dying in diabetic patients at high risk of heart complications. The study prompted at least one analyst to predict the drug could bring in billions of dollars by the end of the decade.
Lilly shares jump on latest data from diabetes drug
A diabetes pill called Jardiance sold by Eli Lilly and Co. cut deaths from heart attacks and strokes in thousands of patients, the first drug to show promise in helping subdue two of the world’s most rampant health epidemics.